IMPAX Laboratories, Inc. - Product Pipeline Review - Q4 2010

Global Markets Direct, December 2010, Pages: 44

IMPAX Laboratories, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “IMPAX Laboratories, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- IMPAX Laboratories, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of IMPAX Laboratories, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of IMPAX Laboratories, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the IMPAX Laboratories, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate IMPAX Laboratories, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of IMPAX Laboratories, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the IMPAX Laboratories, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with IMPAX Laboratories, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of IMPAX Laboratories, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
IMPAX Laboratories, Inc. Snapshot
IMPAX Laboratories, Inc. Overview
Key Information
Key Facts
IMPAX Laboratories, Inc. – Research and Development Overview
Key Therapeutic Areas
IMPAX Laboratories, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
IMPAX Laboratories, Inc. – Pipeline Products Glance
IMPAX Laboratories, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
IMPAX Laboratories, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
IMPAX Laboratories, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
IMPAX Laboratories, Inc. – Drug Profiles
IPX056
Product Description
Mechanism of Action
R&D Progress
IPX066
Product Description
Mechanism of Action
R&D Progress
IPX054
Product Description
Mechanism of Action
R&D Progress
FE158
Product Description
Mechanism of Action
R&D Progress
FE159
Product Description
Mechanism of Action
R&D Progress
FE152
Product Description
Mechanism of Action
R&D Progress
IMPAX Laboratories, Inc. – Pipeline Analysis
IMPAX Laboratories, Inc. – Pipeline Products by Therapeutic Class
IMPAX Laboratories, Inc. Pipeline Products By Target
IMPAX Laboratories, Inc. – Pipeline Products by Route of Administration
IMPAX Laboratories, Inc. – Pipeline Products by Molecule Type
IMPAX Laboratories, Inc. – Recent Pipeline Updates
IMPAX Laboratories, Inc. – Company Statement
IMPAX Laboratories, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Nov 22, 2010: Impax Receives Tentative FDA Approval For Generic Cymbalta Delayed-Release Capsules
Nov 22, 2010: Impax Receives Tentative FDA Approval For Generic Cymbalta Delayed-Release Capsules
Nov 22, 2010: Impax Receives Tentative FDA Approval For Generic Cymbalta Delayed-Release Capsules
Nov 22, 2010: Impax Receives Tentative FDA Approval For Generic Cymbalta Delayed-Release Capsules
Nov 18, 2010: Impax Announces IPX066 Demonstrates Efficacy And Safety In APEX-PD Phase III Study In Treatment Of Early Parkinson's Disease
Nov 16, 2010: Impax Laboratories Receives Final FDA Approval For Generic Allegra-D 60mg/120mg Tablets
Aug 25, 2010: Impax Completes Enrollment In Phase III Trial Of IPX066 For Treatment Of Parkinson's Disease
Jul 22, 2010: Impax Receives Final FDA Approval For Generic OPANA ER Tablets
Apr 15, 2010: Impax Completes Enrollment In APEX-PD Phase III Trial Of IPX066 In Parkinson's Disease
Mar 02, 2010: Impax Receives Final FDA Approval For Generic FLOMAX 0.4mg Capsules
Financial Deals Landscape
IMPAX Laboratories, Inc., Deals Volume Summary, 2004 to YTD 2010
IMPAX Laboratories, Inc., Deals Summary By Region, 2004 to YTD 2010
IMPAX Laboratories, Inc., Deals Summary, 2004 to YTD 2010
IMPAX Laboratories, Inc. Detailed Deal Summary
Asset Purchase
Impax Laboratories Acquires Abbreviated New Drug Applications Rights From Watson Pharmaceuticals
IMPAX Laboratories Enters Into Co-Promotion Agreement With Wyeth
Medicis Pharmaceutical Enters Into An Agreement With IMPAX Laboratories
IMPAX Laboratories Enters Into Co-Marketing Agreement With Leiner Health Products
Licensing Agreements
Medicis Pharmaceutical Enters Into Licensing Agreement With IMPAX Laboratories
Wyeth Enters Into Agreement With IMPAX
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Sports and Fitness Nutrition - Global Strategic Business Report
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Aerospace and Defense Industry - Global Strategic Business Report
• eLEARNING - Global Strategic Business Report
• Charter Schools - Global Outlook
• The Future of the Biodefense Industry: Regulation, Funding Opportunities & Company Profiles
• Education Services - Global Strategic Business Report
• International Military and Civilian Unmanned Aerial Vehicle Survey
• Generic Defense Strategies: Lifecycle Management Strategies to Maximize Revenue in the Face of Growing Generic Competition